BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9562828)

  • 1. Angiotensin II receptor blockers in hypertension and renal disease.
    Bakris GL
    Hosp Pract (1995); 1998 Apr; 33(4):19-22. PubMed ID: 9562828
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
    Siragy HM; Carey RM
    Curr Hypertens Rep; 2000 Apr; 2(2):163-4. PubMed ID: 10981143
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiology patient page. Angiotensin receptor blockers.
    Terra SG
    Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
    [No Abstract]   [Full Text] [Related]  

  • 4. AT1-receptor blockers.
    Petkun W
    Eur Heart J; 2000 Feb; 21(4):335-7. PubMed ID: 10653684
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
    Coats AJ
    Int J Cardiol; 2001 Jul; 79(2-3):99-102. PubMed ID: 11461726
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
    Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fast-acting sartan. High blood pressure therapy without long waiting time].
    MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866306
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lowering blood pressure with sartans. Are there differences?].
    MMW Fortschr Med; 2002 Nov; 144(47):63. PubMed ID: 12532530
    [No Abstract]   [Full Text] [Related]  

  • 10. Valsartan treatment of hypertension--does VALUE add value?
    Lindholm LH
    Lancet; 2004 Jun; 363(9426):2010-1. PubMed ID: 15207946
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension.
    Plum J; Bünten B; Németh R; Grabensee B
    Nephrol Dial Transplant; 1999; 14 Suppl 4():25-7. PubMed ID: 10463202
    [No Abstract]   [Full Text] [Related]  

  • 12. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
    Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract]   [Full Text] [Related]  

  • 13. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract]   [Full Text] [Related]  

  • 16. Sartans for hypertension--implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
    Cheung BM
    Hong Kong Med J; 2004 Oct; 10(5):359. PubMed ID: 15479968
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin type 1 receptor blockers in chronic kidney disease.
    Suzuki H
    Contrib Nephrol; 2004; 143():159-66. PubMed ID: 15248363
    [No Abstract]   [Full Text] [Related]  

  • 18. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
    Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
    Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palatability of angiotensin II antagonists among nephropathic children.
    Meier CM; Simonetti GD; Ghiglia S; Fossali E; Salice P; Limoni C; Bianchetti MG;
    Br J Clin Pharmacol; 2007 May; 63(5):628-31. PubMed ID: 17302913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.